Multi-drug TB Therapy via Molecular Pathway Crossover Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis treatments, especially for multi-drug resistant and extensively drug-resistant TB, face challenges due to the complexity of drug interactions and the need for prolonged regimens, leading to inefficiencies and patient compliance issues.
Innovation Solution
A pharmaceutical composition comprising a combination of clofazimine, ethambutol, pyrazinamide, and either prothionamide or bedaquiline, administered either sequentially or concurrently, which is optimized using a Feedback System Control optimization scheme to determine effective drug-dose combinations, offering alternative treatment options that can be more rapid and effective than standard regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-drug therapies are developed through empirical testing, then treatment effectiveness can be improved, but the development process becomes extremely complex and time-consuming due to the large testing parametric space
Solution Approach 1:
The patent transforms the drug combination development from empirical parameter testing to a systematic approach based on molecular target interactions. By changing the parameters from drug concentrations to molecular pathway crossover patterns, the invention reduces the testing space while maintaining treatment effectiveness.
Solution Approach 2:
The patent introduces molecular target interaction analysis as an intermediary between drug selection and combination optimization. This mediator layer allows prediction of effective combinations through pathway crossover analysis, avoiding exhaustive empirical testing of all possible drug pairs.
2Reliability
If multiple drugs are combined at different concentrations to optimize therapy, then treatment efficacy improves, but the search for optimal combinations becomes a major challenge due to the large testing parametric space
Solution Approach 1:
The patent performs preliminary analysis of molecular target interactions and pathway crossovers before conducting drug combination testing. By pre-identifying potential synergistic interactions through target-based screening, the invention reduces the time required to search for optimal combinations.
Solution Approach 2:
The patent segments the drug combination search space into discrete molecular pathway interactions. By dividing the complex testing problem into manageable pathway crossover segments, the invention enables systematic identification of effective combinations without exhaustive testing.
3Reliability
If standard treatment regimens are used for multi-drug resistant TB, then treatment can be administered, but the treatment duration becomes prolonged and patient compliance deteriorates
Solution Approach 1:
The patent implements a feedback mechanism where molecular target interaction data informs drug combination selection. By continuously analyzing pathway crossover patterns and adjusting combinations accordingly, the invention accelerates treatment response and reduces duration while maintaining availability for resistant strains.
Solution Approach 2:
The patent changes the treatment approach from fixed standard regimens to dynamically optimized combinations based on molecular target analysis. This parameter change enables shorter treatment durations by selecting combinations with proven synergistic interactions against resistant strains.
Data Source
AI summary
The present invention is directed to methods of treating tuberculosis by providing a pharmaceutically effective amount of a combination of drug compounds.